Adicet Cost Of Revenue vs Income Before Tax Analysis

ACET Stock

USD 1.45 0.10 7.41%

Adicet Bio financial indicator trend analysis is way more than just evaluating Adicet Bio prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Adicet Bio is a good investment. Please check the relationship between Adicet Bio Cost Of Revenue and its Income Before Tax accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adicet Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

For more information on how to buy Adicet Stock please use our How to Invest in Adicet Bio guide.

Cost Of Revenue vs Income Before Tax

Cost Of Revenue vs Income Before Tax Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Adicet Bio Cost Of Revenue account and Income Before Tax. At this time, the significance of the direction appears to have strong relationship.

The correlation between Adicet Bio's Cost Of Revenue and Income Before Tax is 0.78. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Income Before Tax in the same time period over historical financial statements of Adicet Bio, assuming nothing else is changed. The correlation between historical values of Adicet Bio's Cost Of Revenue and Income Before Tax is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of Adicet Bio are associated (or correlated) with its Income Before Tax. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Income Before Tax has no effect on the direction of Cost Of Revenue i.e., Adicet Bio's Cost Of Revenue and Income Before Tax go up and down completely randomly.

Correlation Coefficient

0.78

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Cost Of Revenue

Cost of Revenue is found on Adicet Bio income statement and represents the costs associated with goods and services Adicet Bio provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Income Before Tax

Income Before Tax which can also be referred as pre-tax income is reported on Adicet Bio income statement and is an important metric when analyzing Adicet Bio profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.

Most indicators from Adicet Bio's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Adicet Bio current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adicet Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

For more information on how to buy Adicet Stock please use our How to Invest in Adicet Bio guide.At this time, Adicet Bio's Selling General Administrative is comparatively stable compared to the past year. Tax Provision is likely to gain to 0.00 in 2024, despite the fact that Enterprise Value is likely to grow to (54.6 M).

	2023	2024 (projected)
Total Operating Expenses	126.5M	132.8M
Cost Of Revenue	6.1M	5.8M

Total Operating Expenses Cost Of Revenue

Adicet Bio fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Good Will	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Intangible Assets	Common Stock	Net Receivables	Non Currrent Assets Other
Total Assets		-0.13	0.88	0.81	0.41	0.1	-0.47	-0.16	0.49	0.72	0.14	0.93	-0.01	-0.09	-0.04	-0.47	-0.27	0.39	0.13	0.04	0.76	0.96	-0.03	0.69	0.29	0.43
Short Long Term Debt Total	-0.13		-0.09	0.02	0.12	-0.46	-0.31	0.8	0.27	0.0	-0.26	0.01	-0.33	0.96	-0.36	-0.13	0.84	0.65	-0.12	-0.23	0.11	-0.22	0.94	0.0	0.82	-0.88
Other Current Liab	0.88	-0.09		0.95	0.69	-0.14	-0.56	0.11	0.62	0.88	-0.26	0.91	-0.4	-0.09	-0.26	-0.35	-0.29	0.52	0.24	0.13	0.88	0.78	0.02	0.86	0.37	0.43
Total Current Liabilities	0.81	0.02	0.95		0.69	-0.34	-0.6	0.27	0.79	0.97	-0.39	0.86	-0.55	0.04	-0.48	-0.38	-0.15	0.68	0.36	-0.07	0.9	0.7	0.14	0.96	0.51	0.32
Total Stockholder Equity	0.41	0.12	0.69	0.69		-0.38	-0.51	0.44	0.5	0.69	-0.64	0.53	-0.72	0.11	-0.35	-0.12	-0.1	0.59	0.31	0.46	0.59	0.29	0.24	0.7	0.5	0.09
Property Plant And Equipment Net	0.1	-0.46	-0.14	-0.34	-0.38		0.11	-0.82	-0.78	-0.43	0.79	-0.03	0.72	-0.44	0.94	-0.4	-0.35	-0.59	-0.32	0.5	-0.38	0.19	-0.44	-0.45	-0.56	0.27
Current Deferred Revenue	-0.47	-0.31	-0.56	-0.6	-0.51	0.11		-0.24	-0.41	-0.64	0.08	-0.43	0.31	-0.37	0.09	0.63	0.06	-0.77	-0.3	-0.2	-0.37	-0.47	-0.49	-0.64	-0.63	0.24
Net Debt	-0.16	0.8	0.11	0.27	0.44	-0.82	-0.24		0.59	0.3	-0.77	0.08	-0.78	0.75	-0.76	0.14	0.67	0.72	0.07	-0.28	0.35	-0.31	0.77	0.31	0.78	-0.6
Retained Earnings	0.49	0.27	0.62	0.79	0.5	-0.78	-0.41	0.59		0.84	-0.59	0.57	-0.67	0.3	-0.88	-0.06	0.17	0.77	0.39	-0.52	0.75	0.38	0.35	0.85	0.65	0.03
Accounts Payable	0.72	0.0	0.88	0.97	0.69	-0.43	-0.64	0.3	0.84		-0.44	0.75	-0.6	0.03	-0.55	-0.35	-0.18	0.71	0.51	-0.11	0.83	0.63	0.14	0.99	0.51	0.29
Cash	0.14	-0.26	-0.26	-0.39	-0.64	0.79	0.08	-0.77	-0.59	-0.44		-0.11	0.94	-0.2	0.77	-0.35	-0.2	-0.46	-0.22	0.09	-0.41	0.31	-0.26	-0.46	-0.39	0.07
Non Current Assets Total	0.93	0.01	0.91	0.86	0.53	-0.03	-0.43	0.08	0.57	0.75	-0.11		-0.27	0.03	-0.21	-0.43	-0.07	0.48	-0.01	0.01	0.86	0.8	0.1	0.73	0.39	0.35
Cash And Short Term Investments	-0.01	-0.33	-0.4	-0.55	-0.72	0.72	0.31	-0.78	-0.67	-0.6	0.94	-0.27		-0.28	0.75	-0.02	-0.27	-0.64	-0.31	0.07	-0.53	0.17	-0.37	-0.63	-0.54	0.11
Good Will	-0.09	0.96	-0.09	0.04	0.11	-0.44	-0.37	0.75	0.3	0.03	-0.2	0.03	-0.28		-0.36	-0.14	0.83	0.7	-0.15	-0.24	0.03	-0.16	0.99	0.03	0.85	-0.91
Common Stock Shares Outstanding	-0.04	-0.36	-0.26	-0.48	-0.35	0.94	0.09	-0.76	-0.88	-0.55	0.77	-0.21	0.75	-0.36		-0.26	-0.36	-0.61	-0.29	0.63	-0.5	0.08	-0.37	-0.57	-0.53	0.13
Short Term Investments	-0.47	-0.13	-0.35	-0.38	-0.12	-0.4	0.63	0.14	-0.06	-0.35	-0.35	-0.43	-0.02	-0.14	-0.26		-0.11	-0.39	-0.19	-0.13	-0.24	-0.46	-0.23	-0.35	-0.32	0.08
Non Current Liabilities Total	-0.27	0.84	-0.29	-0.15	-0.1	-0.35	0.06	0.67	0.17	-0.18	-0.2	-0.07	-0.27	0.83	-0.36	-0.11		0.41	-0.18	-0.39	-0.04	-0.38	0.78	-0.17	0.62	-0.78
Inventory	0.39	0.65	0.52	0.68	0.59	-0.59	-0.77	0.72	0.77	0.71	-0.46	0.48	-0.64	0.7	-0.61	-0.39	0.41		0.31	-0.18	0.55	0.28	0.78	0.72	0.94	-0.45
Other Current Assets	0.13	-0.12	0.24	0.36	0.31	-0.32	-0.3	0.07	0.39	0.51	-0.22	-0.01	-0.31	-0.15	-0.29	-0.19	-0.18	0.31		-0.06	0.2	0.22	-0.08	0.49	0.2	0.15
Other Stockholder Equity	0.04	-0.23	0.13	-0.07	0.46	0.5	-0.2	-0.28	-0.52	-0.11	0.09	0.01	0.07	-0.24	0.63	-0.13	-0.39	-0.18	-0.06		-0.17	0.06	-0.16	-0.12	-0.18	0.12
Total Liab	0.76	0.11	0.88	0.9	0.59	-0.38	-0.37	0.35	0.75	0.83	-0.41	0.86	-0.53	0.03	-0.5	-0.24	-0.04	0.55	0.2	-0.17		0.61	0.1	0.82	0.43	0.35
Total Current Assets	0.96	-0.22	0.78	0.7	0.29	0.19	-0.47	-0.31	0.38	0.63	0.31	0.8	0.17	-0.16	0.08	-0.46	-0.38	0.28	0.22	0.06	0.61		-0.12	0.61	0.19	0.44
Intangible Assets	-0.03	0.94	0.02	0.14	0.24	-0.44	-0.49	0.77	0.35	0.14	-0.26	0.1	-0.37	0.99	-0.37	-0.23	0.78	0.78	-0.08	-0.16	0.1	-0.12		0.14	0.9	-0.88
Common Stock	0.69	0.0	0.86	0.96	0.7	-0.45	-0.64	0.31	0.85	0.99	-0.46	0.73	-0.63	0.03	-0.57	-0.35	-0.17	0.72	0.49	-0.12	0.82	0.61	0.14		0.51	0.29
Net Receivables	0.29	0.82	0.37	0.51	0.5	-0.56	-0.63	0.78	0.65	0.51	-0.39	0.39	-0.54	0.85	-0.53	-0.32	0.62	0.94	0.2	-0.18	0.43	0.19	0.9	0.51		-0.63
Non Currrent Assets Other	0.43	-0.88	0.43	0.32	0.09	0.27	0.24	-0.6	0.03	0.29	0.07	0.35	0.11	-0.91	0.13	0.08	-0.78	-0.45	0.15	0.12	0.35	0.44	-0.88	0.29	-0.63

Click cells to compare fundamentals

Adicet Bio Account Relationship Matchups

Adicet Bio fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	81.6M	153.8M	338.9M	330.7M	207.3M	215.3M
Short Long Term Debt Total	114.1M	21.6M	20.9M	21.0M	20.9M	19.9M
Other Current Liab	2.8M	(2.8M)	6.7M	12.8M	13.4M	18.3M
Total Current Liabilities	14.9M	14.0M	16.3M	19.7M	19.3M	18.3M
Total Stockholder Equity	(60.4M)	(106.3M)	(168.3M)	(238.1M)	170.2M	178.7M
Property Plant And Equipment Net	2.1M	25.9M	35.0M	49.0M	44.2M	46.4M
Net Debt	103.5M	(62.7M)	(256.6M)	(236.6M)	(138.8M)	(131.8M)
Retained Earnings	(69.6M)	(106.3M)	(168.3M)	(238.1M)	(380.8M)	(361.7M)
Accounts Payable	1.1M	1.6M	3.3M	4.4M	2.6M	2.5M
Cash	10.6M	84.3M	277.5M	257.7M	159.7M	83.6M
Non Current Assets Total	17.4M	59.2M	56.5M	69.7M	45.0M	58.4M
Cash And Short Term Investments	62.4M	94.6M	277.5M	257.7M	159.7M	95.6M
Common Stock Shares Outstanding	2.1M	7.3M	31.0M	41.1M	43.0M	45.2M
Liabilities And Stockholders Equity	81.6M	153.8M	(132.5M)	(199.8M)	207.3M	165.2M
Non Current Liabilities Total	127.1M	246.2M	19.5M	18.6M	17.8M	16.9M
Other Current Assets	179K	363K	2K	380K	2.6M	2.4M
Other Stockholder Equity	137.6M	(106.7M)	(153.9M)	(4K)	550.9M	578.5M
Total Liab	142.0M	44.0M	35.8M	38.4M	37.1M	35.3M
Total Current Assets	64.2M	94.6M	282.4M	261.0M	162.3M	156.9M
Accumulated Other Comprehensive Income	(5.1M)	(41K)	23K	24K	(338.9M)	0.0
Common Stock	1K	3K	4K	2K	3.6K	3.4K
Non Currrent Assets Other	4.7M	12.1M	2.0M	1.2M	822.0K	863.1K

Pair Trading with Adicet Bio

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Adicet Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adicet Bio will appreciate offsetting losses from the drop in the long position's value.

Moving together with Adicet Stock

0.74	EW	Edwards Lifesciences Corp	Pair Corr
0.84	DXCM	DexCom Inc	Pair Corr
0.82	EHAB	Enhabit	Pair Corr
0.77	ABT	Abbott Laboratories Financial Report 18th of July 2024	Pair Corr

Moving against Adicet Stock

0.92	PHG	Koninklijke Philips Earnings Call This Week	Pair Corr
0.9	BSX	Boston Scientific Corp	Pair Corr
0.84	THC	Tenet Healthcare	Pair Corr
0.73	SEM	Select Medical Holdings	Pair Corr
0.72	EHC	Encompass Health Corp	Pair Corr

The ability to find closely correlated positions to Adicet Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Adicet Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Adicet Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Adicet Bio to buy it.

The correlation of Adicet Bio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Adicet Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Adicet Bio moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Adicet Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Adicet Stock Analysis

When running Adicet Bio's price analysis, check to measure Adicet Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adicet Bio is operating at the current time. Most of Adicet Bio's value examination focuses on studying past and present price action to predict the probability of Adicet Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adicet Bio's price. Additionally, you may evaluate how the addition of Adicet Bio to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC